Skip directly to page options Skip directly to A-Z link
Volume 24, Number 4—April 2018
Research

Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014–2016

Mie Ikeda, Megumi Kaneko, Shin-Ichiro Tachibana, Betty Balikagala, Miki Sakurai-Yatsushiro, Shouki Yatsushiro, Nobuyuki Takahashi, Masato Yamauchi, Makoto Sekihara, Muneaki Hashimoto1, Osbert T. Katuro2, Alex Olia3, Paul S. Obwoya, Mary A. Auma, Denis A. Anywar, Emmanuel I. Odongo-Aginya, Joseph Okello-Onen4, Makoto Hirai, Jun Ohashi, Nirianne M.Q. Palacpac, Masatoshi Kataoka, Takafumi Tsuboi, Eisaku Kimura, Toshihiro Horii, and Toshihiro MitaComments to Author 
Author affiliations: Juntendo University School of Medicine, Tokyo, Japan (M. Ikeda, M. Kaneko, S.-I. Tachibana, M. Yamauchi, M. Sekihara, M. Hashimoto, M. Hirai, T. Mita); Ehime University, Matsuyama, Japan (B. Balikagala, T. Tsuboi); Tokyo Women’s Medical University, Tokyo (M. Sakurai-Yatsushiro, N. Takahashi); National Institute of Advanced Industrial Science and Technology, Kagawa, Japan (S. Yatsushiro, M. Kataoka); Med Biotech Laboratories, Kampala, Uganda (O.T. Katuro); Gulu University, Gulu, Uganda (A. Olia, D.A. Anywar, E.I. Odongo-Aginya, J. Okello-Onen); St. Mary’s Hospital Lacor, Gulu (P.S. Obwoya, M.A. Auma); The University of Tokyo, Tokyo (J. Ohashi); Osaka University, Osaka, Japan (N.M.Q. Palacpac, E. Kimura, T. Horii)

Main Article

Table 2

Characteristics of Plasmodium falciparum isolates with high ex vivo ring-stage survival rates and patients enrolled in study of Plasmodium falciparum survival rates, Uganda, 2014–2016*

Sample name Patient age, y Patient sex Signs and symptoms Day 0 parasitemia, % Early ring-stage parasites at day 0, % Mean parasite survival rate, %, ± SEM
H1 3.0 M Fever, headache, cough 0.85 80.4 34.3
H2 2.0 M Fever 15.0 98.2 13.3 ± 1.5
H3 3.2 M Fever 0.76 51.9 18.9 ± 0.9
H4 4.5 F Fever 2.56 72.0 18.1 ± 1.4
3D7 NA NA NA NA NA 0 ± 0
MRA-1236 NA NA NA NA NA 14.3 ± 0.5
MRA-1240 NA NA NA NA NA 27.0 ± 2.7

*Survival rate, parasitemia at 700 nmol/L dihydroartemisinin exposed/parasitemia at 0 nmol/L control × 100; mean value ± SEM in 2 (H2, H3, and H4) and 3 (3D7, MRA-1236, and MRA-1240) independent trials. Day 0, day of enrollment. NA, not applicable.

Main Article

1Current affiliation: National Institute of Advanced Industrial Science and Technology, Kagawa, Japan.

2Current affiliation: Mildmay Uganda-KAMPALA, Kampala, Uganda.

3Current affiliation: Gunma University, Gunma, Japan.

4Deceased.

Page created: March 16, 2018
Page updated: March 16, 2018
Page reviewed: March 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external